Daclizumab induction therapy in liver transplant recipients with renal insufficiency

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 6, 2010, Pages 776-786

  Asrani, S K ^a   Kim, W R ^a,b   Pedersen, R A ^b   Charlton, M R ^a,b   Kremers, W K ^b   Therneau, T M ^b   Rosen, C B ^b   Dean, P G ^b  

^a MAYO CLINIC   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CREATININE; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; STEROID; TACROLIMUS;

ADULT; ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENDER; GRAFT RECIPIENT; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK REDUCTION; SIDE EFFECT; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES;

EID: 77955722627     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04408.x     Document Type: Article

References (25)

1. Encke J, Uhl W, Stremmel W, Sauer P. Immunosuppression and modulation in liver transplantation. Nephrol Dial Transplant 2004 19 (Suppl 4 iv22 5.
2. Eckardt KU. Renal failure in liver disease. Intensive Care Med 1999 25 : 5 14.
3. Porayko MK, Textor SC, Krom RA, et al. Nephrotoxic effects of primary immunosuppression with FK-506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994 69 : 105 111.
4. Varo E, Lopez A, Rivero C. Initial immunosuppression in liver transplant recipients with impaired renal function. Transplant Proc 2005 37 : 3909 3912.
5. Cohen AJ, Stegall MD, Rosen CB, et al. Chronic renal dysfunction late after liver transplantation. Liver Transpl 2002 8 : 916 921.
6. Gonwa TA, Mai ML, Melton LB, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLT) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation 2001 72 : 1934 1939.
7. Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal failure following liver transplantation: a retrospective analysis. Transplantation 1998 66 : 59 66.
8. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003 349 : 931 940.
9. Freeman RB Jr., Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002 8 : 851 858.
10. Carswell CI, Plosker GL, Wagstaff AJ. Daclizumab: a review of its use in the management of organ transplantation. BioDrugs 2001 15 : 745 773.
11. Nashan B, Schlitt HJ, Schwinzer R, et al. Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients. Transplantation 1996 61 : 546 554.
12. Raimondo ML, Burroughs AK. Single-agent immunosuppression after liver transplantation: what is possible? Drugs 2002 62 : 1587 1597.
13. Koch M, Niemeyer G, Patel I, Light S, Nashan B. Pharmacokinetics, pharmacodynamics, and immunodynamics of daclizumab in a two-dose regimen in liver transplantation. Transplantation 2002 73 : 1640 1646. (Pubitemid 34568679)
14. Ernoyan G, Levin N. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002 2 (Suppl 1 S1 266.
15. Coresh J, Stevens LA. Kidney function estimating equations: where do we stand? Curr Opin Nephrol Hypertens 2006 15 : 276 284.
16. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003 139 : 137 147.
17. Kuan Y, Hossain M, Surman J, El Nahas AM, Haylor J. GFR prediction using the MDRD and Cockcroft and Gault equations in patients with end-stage renal disease. Nephrol Dial Transplant 2005 20 : 2394 2401.
18. Moser MA. Options for induction immunosuppression in liver transplant recipients. Drugs 2002 62 : 995 1011.
19. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007 357 : 2562 2575.
20. Ramirez CB, Bozdin A, Frank A, Maley W, Doria C. Optimizing use of basiliximab in liver transplantation. Transplant Research and Risk Management 2010 2 : 1 10.
21. Neuberger JM, Mamelok RD, Neuhaus P, et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. Am J Transplant 2009 9 : 327 336.
22. Emre S, Gondolesi G, Polat K, et al. Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 2001 7 : 220 225.
23. Lin CC, Chuang FR, Lee CH, et al. The renal-sparing efficacy of basiliximab in adult living donor liver transplantation. Liver Transpl 2005 11 : 1258 1264.
24. Yoshida EM, Marotta PJ, Greig PD, et al. Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 2005 11 : 1064 1072.
25. Klintmalm G, Fasola C, Jennings L, et al. Hepatitis C-3 study: Severe HCV recurrence port liver transplantation is decreased in patients treated with mycophenolate mofetil, particularly, in the absence of steroids. Hepatology 2008 48 (Suppl 338A.